Global Carrier Screening Market: Focus on Product Type, Technology Type,18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape – Analysis and Forecast, 2019-2029
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in this Report:
The global carrier screening Industry Analysis by BIS Research projects the market to grow with a double-digit compound annual growth rate between the years 2019 and 2029. The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.
With substantial increase in the demand for carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness an impressive growth and promises to be a lucrative field for investment.
Expert Quote on Global Carrier Screening Market
“North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market values. However, Asia-Pacific is expected to grow at an impressive 15.97% CAGR in the forecast period from 2019 to 2029. Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value.”
Scope of the Market Intelligent on the Global Carrier Screening Market
The purpose of this market analysis is to gain a holistic view of the carrier screening market in terms of various influencing factors, such as trends, technological advancements, and funding scenario in the market. The scope of this report constitutes of an in-depth study of the global carrier screening market, including a thorough analysis of the products across different regions.
Market Segmentation
The global carrier screening market is segmented on the basis of four sections, namely product, technology, disease type, and geography.
Under the global carrier screening market segmentation by product type, the laboratory developed tests sub-segment dominated the global carrier screening market in 2018. However, the NGS-based carrier screening test is expected to witness the highest CAGR in the forecast period from 2019 to 2029.
Under the global carrier screening market segmentation by disease type, down syndrome currently dominates the global carrier screening market. Cystic fibrosis disease type is estimated to witness the highest CAGR in the forecast period.
The global carrier screening market segmentation by region is segregated under five major regions, such as North America, Europe, APAC, Latin America, and Rest-of-the-World. North America was the leading contributor of the global carrier screening market in 2018.
Key Companies in the Carrier Screening Market
The key players which have significant contributions to the carrier screening market include Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.
Key Questions Answered in this Report:
- How the carrier screening market is expected to have an impact on the healthcare industry?
- What was the total revenue generated by the global carrier screening market for autonomous in 2018 and how is it expected to grow during 2019 – 2029?
- How are the transformational trends and major driving forces in this technology are expected to yield new business opportunities?
- Which sub-segment of the global carrier screening market by disease, such as down syndrome, sickle cell anemia, cystic fibrosis, hemophilia, spinal muscular atrophy, fragile x syndrome, thalassemia, other autosomal recessive genetic disorders, during the forecast period, 2019-2029?
- Which region, such as North America, Europe, Asia-Pacific, Latin-America is expected to grow the fastest in the global carrier screening market?
- What are the key developmental strategies which are being implemented by the key players to stand out in this market?
The global carrier screening Industry Analysis by BIS Research projects the market to grow with a double-digit compound annual growth rate between the years 2019 and 2029. The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.
With substantial increase in the demand for carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness an impressive growth and promises to be a lucrative field for investment.
Expert Quote on Global Carrier Screening Market
“North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market values. However, Asia-Pacific is expected to grow at an impressive 15.97% CAGR in the forecast period from 2019 to 2029. Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value.”
Scope of the Market Intelligent on the Global Carrier Screening Market
The purpose of this market analysis is to gain a holistic view of the carrier screening market in terms of various influencing factors, such as trends, technological advancements, and funding scenario in the market. The scope of this report constitutes of an in-depth study of the global carrier screening market, including a thorough analysis of the products across different regions.
Market Segmentation
The global carrier screening market is segmented on the basis of four sections, namely product, technology, disease type, and geography.
Under the global carrier screening market segmentation by product type, the laboratory developed tests sub-segment dominated the global carrier screening market in 2018. However, the NGS-based carrier screening test is expected to witness the highest CAGR in the forecast period from 2019 to 2029.
Under the global carrier screening market segmentation by disease type, down syndrome currently dominates the global carrier screening market. Cystic fibrosis disease type is estimated to witness the highest CAGR in the forecast period.
The global carrier screening market segmentation by region is segregated under five major regions, such as North America, Europe, APAC, Latin America, and Rest-of-the-World. North America was the leading contributor of the global carrier screening market in 2018.
Key Companies in the Carrier Screening Market
The key players which have significant contributions to the carrier screening market include Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.
EXECUTIVE SUMMARY
1 MARKET OVERVIEW
2 MARKET DYNAMICS
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Availability of Advanced Screening Technologies
2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage
2.2.3 Increasing Prevalence of Genetic and Congenital disorders
2.2.4 Increasing Consumer Demand
2.3 Market Restraints
2.3.1 Limited Clinical Experience
2.3.2 General Public May Lack Interest in Expanded Carrier Screening
2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms
2.4 Market Opportunities
2.4.1 Genetic Counselling Needs to be Adapted for Expanded Carrier Screening Services
2.4.2 Availability of Direct-to-Consumer Tests
2.4.3 Capitalizing on the Potential Presented by the Emerging Markets of Asia
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Collaborations, Partnerships, Joint Ventures, and Agreements
3.1.2 Business Expansion and Funding
3.1.3 Product Launch and Enhancements
3.1.4 Mergers and Acquisitions
3.2 Market Share Analysis
4 INDUSTRY INSIGHTS
4.1 Appropriate Use Criteria
4.1.1 Carrier Screening for Familial Disease
4.1.1.1 Fragile X
4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases
4.1.2.1 Cystic Fibrosis
4.1.2.2 Spinal Muscular Atrophy
4.1.2.3 Hemoglobinopathies
4.1.2.4 Ashkenazi Jewish Carrier Screening
4.1.3 Other Ethnicities
4.2 American College of Obstetricians and Gynecologists (ACOG)
4.3 American College of Medical Genetics and Genomics (ACMG)
4.4 U.S. Food and Drug Administration (FDA)
5 GLOBAL CARRIER SCREENING MARKET (BY PRODUCT TYPE)
5.1 Laboratory Developed Tests (LDT)
5.2 Kits and Assays
6 GLOBAL CARRIER SCREENING MARKET (BY DISEASE)
6.1 Down Syndrome
6.2 Sickle Cell Anemia
6.3 Cystic Fibrosis
6.4 Hemophilia
6.5 Spinal Muscular Atrophy
6.6 Fragile X Syndrome
6.7 Thalassemia
6.8 Other Autosomal Recessive Genetic Disorders
7 GLOBAL CARRIER SCREENING MARKET (BY REGION)
7.1 North America
7.1.1 North America: Market Dynamics
7.1.2 North America Carrier Screening Market (by Country)
7.1.2.1 U.S.
7.1.2.2 Canada
7.2 Europe
7.2.1 Europe: Market Dynamics
7.2.2 Europe Carrier Screening Market (by Country)
7.2.2.1 Germany
7.2.2.2 U.K.
7.2.2.3 France
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 The Netherlands
7.2.2.7 Belgium
7.2.2.8 Switzerland
7.2.2.9 Denmark
7.2.2.10 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 Asia-Pacific: Market Dynamics
7.3.2 Asia-Pacific, by Country
7.3.2.1 China
7.3.2.2 Japan
7.3.2.3 Australia
7.3.2.4 India
7.3.2.5 South Korea
7.3.2.6 Singapore
7.3.2.7 Rest-of-the-Asia-Pacific
7.4 Latin America
7.4.1 Latin America: Market Dynamics
7.4.2 Latin America, by Country
7.4.2.1 Brazil
7.4.2.2 Mexico
7.4.2.3 Rest-of-Latin America
7.5 Rest-of-the-World
8 COMPANY PROFILES
8.1 Overview
8.2 23andMe, Inc.
8.2.1 Company Overview
8.2.2 Role of 23andMe, Inc. in the Global Carrier Screening Market
8.2.3 SWOT Analysis
8.3 BGI
8.3.1 Company Overview
8.3.2 Role of BGI in the Global Carrier Screening Market
8.3.3 SWOT Analysis
8.4 CENTOGENE AG
8.4.1 Company Overview
8.4.2 Role of CENTOGENE AG in the Global Carrier Screening Market
8.4.3 SWOT Analysis
8.5 Eurofins Scientific
8.5.1 Company Overview
8.5.2 Role of Eurofins Scientific in the Global Carrier Screening Market
8.5.3 Financials
8.5.4 SWOT Analysis
8.6 Gene By Gene
8.6.1 Company Overview
8.6.2 Role of Gene By Gene in the Global Carrier Screening Market
8.6.3 SWOT Analysis
8.7 GenMark Diagnostics, Inc.
8.7.1 Company Overview
8.7.2 Role of GenMark Diagnostics, Inc. in the Global Carrier Screening Market
8.7.3 Financials
8.7.4 Key Insights about Financial Health of the Company
8.7.5 SWOT Analysis
8.8 Illumina, Inc.
8.8.1 Company Overview
8.8.2 Role of Illumina, Inc. in the Global Carrier Screening Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Invitae Corporation
8.9.1 Company Overview
8.9.2 Role of Invitae Corporation in the Global Carrier Screening Market
8.9.3 Financials
8.9.4 Key Insights about Financial Health of the Company
8.9.5 SWOT Analysis
8.10 Laboratory Corporation of America Holdings
8.10.1 Company Overview
8.10.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market
8.10.3 Financials
8.10.4 SWOT Analysis
8.11 Myriad Genetics, Inc.
8.11.1 Company Overview
8.11.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market
8.11.3 Financials
8.11.4 SWOT Analysis
8.12 Natera, Inc.
8.12.1 Company Overview
8.12.2 Role of Natera, Inc. in the Global Carrier Screening Market
8.12.3 Financials
8.12.3.1 Key Insights of the Financial Health about the Company
8.12.4 SWOT Analysis
8.13 Pathway Genomics Corporation
8.13.1 Company Overview
8.13.2 Role of Pathway Genomics Corporation in the Global Carrier Screening Market
8.13.3 SWOT Analysis
8.14 Quest Diagnostics Incorporated
8.14.1 Company Overview
8.14.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
8.14.3 Financials
8.14.4 SWOT Analysis
8.15 Sema4
8.15.1 Company Overview
8.15.2 Role of Sema4 in the Global Carrier Screening Market
8.15.3 SWOT Analysis
8.16 Thermo Fisher Scientific Inc.
8.16.1 Company Overview
8.16.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
8.16.3 Financials
8.16.4 Key Insights about Financial Health of the Company
8.16.5 SWOT Analysis
1 MARKET OVERVIEW
2 MARKET DYNAMICS
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Availability of Advanced Screening Technologies
2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage
2.2.3 Increasing Prevalence of Genetic and Congenital disorders
2.2.4 Increasing Consumer Demand
2.3 Market Restraints
2.3.1 Limited Clinical Experience
2.3.2 General Public May Lack Interest in Expanded Carrier Screening
2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms
2.4 Market Opportunities
2.4.1 Genetic Counselling Needs to be Adapted for Expanded Carrier Screening Services
2.4.2 Availability of Direct-to-Consumer Tests
2.4.3 Capitalizing on the Potential Presented by the Emerging Markets of Asia
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Collaborations, Partnerships, Joint Ventures, and Agreements
3.1.2 Business Expansion and Funding
3.1.3 Product Launch and Enhancements
3.1.4 Mergers and Acquisitions
3.2 Market Share Analysis
4 INDUSTRY INSIGHTS
4.1 Appropriate Use Criteria
4.1.1 Carrier Screening for Familial Disease
4.1.1.1 Fragile X
4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases
4.1.2.1 Cystic Fibrosis
4.1.2.2 Spinal Muscular Atrophy
4.1.2.3 Hemoglobinopathies
4.1.2.4 Ashkenazi Jewish Carrier Screening
4.1.3 Other Ethnicities
4.2 American College of Obstetricians and Gynecologists (ACOG)
4.3 American College of Medical Genetics and Genomics (ACMG)
4.4 U.S. Food and Drug Administration (FDA)
5 GLOBAL CARRIER SCREENING MARKET (BY PRODUCT TYPE)
5.1 Laboratory Developed Tests (LDT)
5.2 Kits and Assays
6 GLOBAL CARRIER SCREENING MARKET (BY DISEASE)
6.1 Down Syndrome
6.2 Sickle Cell Anemia
6.3 Cystic Fibrosis
6.4 Hemophilia
6.5 Spinal Muscular Atrophy
6.6 Fragile X Syndrome
6.7 Thalassemia
6.8 Other Autosomal Recessive Genetic Disorders
7 GLOBAL CARRIER SCREENING MARKET (BY REGION)
7.1 North America
7.1.1 North America: Market Dynamics
7.1.2 North America Carrier Screening Market (by Country)
7.1.2.1 U.S.
7.1.2.2 Canada
7.2 Europe
7.2.1 Europe: Market Dynamics
7.2.2 Europe Carrier Screening Market (by Country)
7.2.2.1 Germany
7.2.2.2 U.K.
7.2.2.3 France
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 The Netherlands
7.2.2.7 Belgium
7.2.2.8 Switzerland
7.2.2.9 Denmark
7.2.2.10 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 Asia-Pacific: Market Dynamics
7.3.2 Asia-Pacific, by Country
7.3.2.1 China
7.3.2.2 Japan
7.3.2.3 Australia
7.3.2.4 India
7.3.2.5 South Korea
7.3.2.6 Singapore
7.3.2.7 Rest-of-the-Asia-Pacific
7.4 Latin America
7.4.1 Latin America: Market Dynamics
7.4.2 Latin America, by Country
7.4.2.1 Brazil
7.4.2.2 Mexico
7.4.2.3 Rest-of-Latin America
7.5 Rest-of-the-World
8 COMPANY PROFILES
8.1 Overview
8.2 23andMe, Inc.
8.2.1 Company Overview
8.2.2 Role of 23andMe, Inc. in the Global Carrier Screening Market
8.2.3 SWOT Analysis
8.3 BGI
8.3.1 Company Overview
8.3.2 Role of BGI in the Global Carrier Screening Market
8.3.3 SWOT Analysis
8.4 CENTOGENE AG
8.4.1 Company Overview
8.4.2 Role of CENTOGENE AG in the Global Carrier Screening Market
8.4.3 SWOT Analysis
8.5 Eurofins Scientific
8.5.1 Company Overview
8.5.2 Role of Eurofins Scientific in the Global Carrier Screening Market
8.5.3 Financials
8.5.4 SWOT Analysis
8.6 Gene By Gene
8.6.1 Company Overview
8.6.2 Role of Gene By Gene in the Global Carrier Screening Market
8.6.3 SWOT Analysis
8.7 GenMark Diagnostics, Inc.
8.7.1 Company Overview
8.7.2 Role of GenMark Diagnostics, Inc. in the Global Carrier Screening Market
8.7.3 Financials
8.7.4 Key Insights about Financial Health of the Company
8.7.5 SWOT Analysis
8.8 Illumina, Inc.
8.8.1 Company Overview
8.8.2 Role of Illumina, Inc. in the Global Carrier Screening Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Invitae Corporation
8.9.1 Company Overview
8.9.2 Role of Invitae Corporation in the Global Carrier Screening Market
8.9.3 Financials
8.9.4 Key Insights about Financial Health of the Company
8.9.5 SWOT Analysis
8.10 Laboratory Corporation of America Holdings
8.10.1 Company Overview
8.10.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market
8.10.3 Financials
8.10.4 SWOT Analysis
8.11 Myriad Genetics, Inc.
8.11.1 Company Overview
8.11.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market
8.11.3 Financials
8.11.4 SWOT Analysis
8.12 Natera, Inc.
8.12.1 Company Overview
8.12.2 Role of Natera, Inc. in the Global Carrier Screening Market
8.12.3 Financials
8.12.3.1 Key Insights of the Financial Health about the Company
8.12.4 SWOT Analysis
8.13 Pathway Genomics Corporation
8.13.1 Company Overview
8.13.2 Role of Pathway Genomics Corporation in the Global Carrier Screening Market
8.13.3 SWOT Analysis
8.14 Quest Diagnostics Incorporated
8.14.1 Company Overview
8.14.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
8.14.3 Financials
8.14.4 SWOT Analysis
8.15 Sema4
8.15.1 Company Overview
8.15.2 Role of Sema4 in the Global Carrier Screening Market
8.15.3 SWOT Analysis
8.16 Thermo Fisher Scientific Inc.
8.16.1 Company Overview
8.16.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
8.16.3 Financials
8.16.4 Key Insights about Financial Health of the Company
8.16.5 SWOT Analysis
LIST OF TABLES
Table 2.1: Impact Analysis
Table 4.1: ACMG: American College of Medical Genetics and Genomics; ACOG: American College of Obstetricians and Gynecologists: Recommendations for Risk-Based Screening
Table 4.2: List of Regulatory Authorities involved in CLIA Program
Table 4.3: Regulatory Bodies
Table 2.1: Impact Analysis
Table 4.1: ACMG: American College of Medical Genetics and Genomics; ACOG: American College of Obstetricians and Gynecologists: Recommendations for Risk-Based Screening
Table 4.2: List of Regulatory Authorities involved in CLIA Program
Table 4.3: Regulatory Bodies
LIST OF FIGURES
Figure 1: Drivers and Restraints of Carrier Screening Market
Figure 2: Key Strategies Incorporated by Stakeholders of Carrier Screening Market, to Sustain the Competition (from January 2015 to May 2019)
Figure 3: Global Carrier Screening Market, 2018-2029
Figure 4: Global Carrier Screening Market Share (by Product), 2018 and 2029
Figure 5: Global Carrier Screening LDT Market Share (by Technology), 2018 and 2029
Figure 6: Global Carrier Screening Market Share (by Disease Type), 2018 and 2029
Figure 7: Global Carrier Screening Market Share (by Region), 2018 and 2029
Figure 1.1: End-to-End Practice Workflow Support for Genetic Screening
Figure 1.2: Autosomal Recessive Inheritance of Harmful Mutations
Figure 1.3: The Journey to Expanded Carrier Screening
Figure 2.1: Market Dynamics of Global Carrier Screening Market
Figure 3.1: Competitive Landscape, January 2015-May 2019
Figure 3.2: Share of Key Developments and Strategies, January 2015-May 2019
Figure 3.3: Collaborations, Partnership, Joint Ventures, and Agreements Share (by Company), January 2015-May 2019
Figure 3.4: Business Expansion and FundingShare (by Company), January 2015-May 2019
Figure 3.5: Product Launches, Enhancements, Approvals, and Upgradation Share (by Company), January 2015-May 2019
Figure 3.6: Mergers and Acquisitions Share (by Company), January 2015-May 2019
Figure 3.7: Market Share Analysis (by Company) for the Global Carrier Screening Market, 2018
Figure 4.1: Classification of Tests in CLIA Program
Figure 5.1: Global carrier screening Market (by Product Type)
Figure 5.2: Global Carrier Screening Market (by Product Type), 2018 and 2029
Figure 5.3: Key players of Carrier Screening Test Market
Figure 5.4: Global Carrier Screening Test Market, 2018-2029
Figure 5.5: Global Carrier Screening Test Market (by Technology), 2018 and 2029, $Million
Figure 5.6: Global Carrier Screening Laboratory Developed Test Market (NGS Technology), 2018-2029, $Million
Figure 5.7: Global Carrier Screening Laboratory Developed Test Market (PCR Technology), 2018-2029, $Million
Figure 5.8: Global Carrier Screening Laboratory Developed Test Market (Other Technology), 2018-2029, $Million
Figure 5.9: Key Players of the Kits and Assays Associated with Carrier Screening Market
Figure 5.10: Global Carrier Screening Kits and Assays Market, 2018-2029
Figure 6.1: Different Types of Autosomal Recessive Genetic Diseases
Figure 6.2: Global Carrier Screening Market (by Disease), 2018 and 2029
Figure 6.3: Global Carrier Screening Market (Down Syndrome), 2018-2029
Figure 6.4: Global Carrier Screening Market (Sickle Cell Anemia), 2018-2029
Figure 6.5: Global Carrier Screening Market (Cystic Fibrosis), 2018-2029
Figure 6.6: Global Carrier Screening Market (Hemophilia), 2018-2029
Figure 6.7: Global Carrier Screening Market (Spinal Muscular Atrophy), 2018-2029
Figure 6.8: Global Carrier Screening Market (Fragile X Syndrome), 2018-2029
Figure 6.9: Global Carrier Screening Market (Thalassemia), 2018-2029
Figure 6.10: Global Carrier Screening Market (Other Autosomal Recessive Genetic disorders), 2018-2029
Figure 7.1: Global Carrier Screening Market (by Region), 2019 and 2029
Figure 7.2: North America: Carrier Screening Market, (2018-2029)
Figure 7.3: North America: Market Dynamics
Figure 7.4: North America: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.5: The U.S.: Carrier Screening Market, 2018-2029
Figure 7.6: Canada: Carrier Screening Market, 2018-2029
Figure 7.7: Europe: Carrier Screening Market (2018-2029)
Figure 7.8: Europe: Market Dynamics
Figure 7.9: Europe: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.10: Germany: Carrier Screening Market (2018-2029)
Figure 7.11: U.K.: Carrier Screening Market, 2018-2029
Figure 7.12: France: Carrier Screening Market, 2018-2029
Figure 7.13: Italy: Carrier Screening Market, 2018-2029
Figure 7.14: Spain: Carrier Screening Market, 2018-2029
Figure 7.15: The Netherlands: Carrier Screening Market, 2018-2029
Figure 7.16: Belgium: Carrier Screening Market, 2018-2029
Figure 7.17: Switzerland: Carrier Screening Market, 2018-2029
Figure 7.18: Denmark: Carrier Screening Market, 2018-2029
Figure 7.19: Rest-of-Europe: Carrier Screening Market, 2018-2029
Figure 7.20: Asia-Pacific: Carrier Screening Market, (2018-2029)
Figure 7.21: Asia-Pacific: Market Dynamics
Figure 7.22: Asia-Pacific: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.23: China: Carrier Screening Market, 2018-2029
Figure 7.24: Japan: Carrier Screening Market, 2018-2029
Figure 7.25: Australia: Carrier Screening Market, 2018-2029
Figure 7.26: India: Carrier Screening Market, 2018-2029
Figure 7.27: South Korea: Carrier Screening Market, 2018-2029
Figure 7.28: Singapore: Carrier Screening Market, 2018-2029
Figure 7.29: Rest-of-the-Asia-Pacific: Carrier Screening Market, 2018-2029
Figure 7.30: Latin America: Carrier Screening Market, (2018-2029)
Figure 7.31: Latin America: Market Dynamics
Figure 7.32: Latin America: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.33: Brazil: Carrier Screening Market, 2018-2029
Figure 7.34: Mexico: Carrier Screening Market, 2018-2029
Figure 7.35: Rest-of-Latin America: Carrier Screening Market, 2018-2029
Figure 7.36: Rest-of-the-World: Carrier Screening Market, 2018-2029
Figure 8.1: Shares of Key Company Profiles
Figure 8.2: 23and Me, Inc.: Overall Product Portfolio
Figure 8.3: 23andMe Inc.: SWOT Analysis
Figure 8.4: BGI Product Offerings for Global Carrier Screening Market
Figure 8.5: BGI: SWOT Analysis
Figure 8.6: CENTOGENE AG: Overall Product Portfolio
Figure 8.7: CENTOGENE AG: SWOT Analysis
Figure 8.8: Eurofins Scientific: Overall Product Portfolio
Figure 8.9: Eurofins Scientific: Overall Financials, 2016-2018
Figure 8.10: Eurofins Scientific: Revenue (by Region), 2016-2018
Figure 8.11: Eurofins Scientific: SWOT Analysis
Figure 8.12: Gene by Gene: Overall Product Portfolio
Figure 8.13: Gene By Gene: SWOT Analysis
Figure 8.14: GenMark Diagnostics, Inc.: Overall Product Portfolio
Figure 8.15: GenMark Diagnostics, Inc.: Overall Financials, 2016-2018
Figure 8.16: GenMark Diagnostics, Inc.: R&D Expenditure, 2016-2018
Figure 8.17: GenMark Diagnostics, Inc.: SWOT Analysis
Figure 8.18: Illumina, Inc.: Overall Product Portfolio
Figure 8.19: Illumina, Inc.: Overall Financials, 2016-2018
Figure 8.20: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 8.21: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 8.22: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 8.23: Illumina, Inc.: SWOT Analysis
Figure 8.24: Invitae Corporation: Overall Product Portfolio
Figure 8.25: Invitae Corporation: Overall Financials, 2016-2018
Figure 8.26: Invitae Corporation: Revenue (by Region), 2016-2018
Figure 8.27: Invitae Corporation: R&D Expenditure, 2016-2018
Figure 8.28: Invitae Corporation: SWOT Analysis
Figure 8.29: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 8.30: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 8.31: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 8.32: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 8.33: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 8.34: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 8.35: Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 8.36: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 8.37: Myriad Genetics, Inc.: SWOT Analysis
Figure 8.38: Natera, Inc.: Overall Product Portfolio
Figure 8.39: Natera, Inc.: Overall Financials, 2016-2018
Figure 8.40: Natera, Inc.: Revenue (by Business Segment), 2016-2018
Figure 8.41: Natera, Inc.: R&D Expense, 2016-2018
Figure 8.42: Natera, Inc.: SWOT Analysis
Figure 8.43: Pathway Genomics Corporation: Overall Product Portfolio
Figure 8.44: Pathway Genomics Corporation: SWOT Analysis
Figure 8.45: Product Portfolio: Quest Diagnostics Incorporated
Figure 8.46: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 8.47: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 8.48: Quest Diagnostics Incorporated: SWOT Analysis
Figure 8.49: Sema4: Overall Product Portfolio
Figure 8.50: Sema4: SWOT Analysis
Figure 8.51: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 8.52: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 8.53: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 8.54: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 8.55: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 8.56: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 1: Drivers and Restraints of Carrier Screening Market
Figure 2: Key Strategies Incorporated by Stakeholders of Carrier Screening Market, to Sustain the Competition (from January 2015 to May 2019)
Figure 3: Global Carrier Screening Market, 2018-2029
Figure 4: Global Carrier Screening Market Share (by Product), 2018 and 2029
Figure 5: Global Carrier Screening LDT Market Share (by Technology), 2018 and 2029
Figure 6: Global Carrier Screening Market Share (by Disease Type), 2018 and 2029
Figure 7: Global Carrier Screening Market Share (by Region), 2018 and 2029
Figure 1.1: End-to-End Practice Workflow Support for Genetic Screening
Figure 1.2: Autosomal Recessive Inheritance of Harmful Mutations
Figure 1.3: The Journey to Expanded Carrier Screening
Figure 2.1: Market Dynamics of Global Carrier Screening Market
Figure 3.1: Competitive Landscape, January 2015-May 2019
Figure 3.2: Share of Key Developments and Strategies, January 2015-May 2019
Figure 3.3: Collaborations, Partnership, Joint Ventures, and Agreements Share (by Company), January 2015-May 2019
Figure 3.4: Business Expansion and FundingShare (by Company), January 2015-May 2019
Figure 3.5: Product Launches, Enhancements, Approvals, and Upgradation Share (by Company), January 2015-May 2019
Figure 3.6: Mergers and Acquisitions Share (by Company), January 2015-May 2019
Figure 3.7: Market Share Analysis (by Company) for the Global Carrier Screening Market, 2018
Figure 4.1: Classification of Tests in CLIA Program
Figure 5.1: Global carrier screening Market (by Product Type)
Figure 5.2: Global Carrier Screening Market (by Product Type), 2018 and 2029
Figure 5.3: Key players of Carrier Screening Test Market
Figure 5.4: Global Carrier Screening Test Market, 2018-2029
Figure 5.5: Global Carrier Screening Test Market (by Technology), 2018 and 2029, $Million
Figure 5.6: Global Carrier Screening Laboratory Developed Test Market (NGS Technology), 2018-2029, $Million
Figure 5.7: Global Carrier Screening Laboratory Developed Test Market (PCR Technology), 2018-2029, $Million
Figure 5.8: Global Carrier Screening Laboratory Developed Test Market (Other Technology), 2018-2029, $Million
Figure 5.9: Key Players of the Kits and Assays Associated with Carrier Screening Market
Figure 5.10: Global Carrier Screening Kits and Assays Market, 2018-2029
Figure 6.1: Different Types of Autosomal Recessive Genetic Diseases
Figure 6.2: Global Carrier Screening Market (by Disease), 2018 and 2029
Figure 6.3: Global Carrier Screening Market (Down Syndrome), 2018-2029
Figure 6.4: Global Carrier Screening Market (Sickle Cell Anemia), 2018-2029
Figure 6.5: Global Carrier Screening Market (Cystic Fibrosis), 2018-2029
Figure 6.6: Global Carrier Screening Market (Hemophilia), 2018-2029
Figure 6.7: Global Carrier Screening Market (Spinal Muscular Atrophy), 2018-2029
Figure 6.8: Global Carrier Screening Market (Fragile X Syndrome), 2018-2029
Figure 6.9: Global Carrier Screening Market (Thalassemia), 2018-2029
Figure 6.10: Global Carrier Screening Market (Other Autosomal Recessive Genetic disorders), 2018-2029
Figure 7.1: Global Carrier Screening Market (by Region), 2019 and 2029
Figure 7.2: North America: Carrier Screening Market, (2018-2029)
Figure 7.3: North America: Market Dynamics
Figure 7.4: North America: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.5: The U.S.: Carrier Screening Market, 2018-2029
Figure 7.6: Canada: Carrier Screening Market, 2018-2029
Figure 7.7: Europe: Carrier Screening Market (2018-2029)
Figure 7.8: Europe: Market Dynamics
Figure 7.9: Europe: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.10: Germany: Carrier Screening Market (2018-2029)
Figure 7.11: U.K.: Carrier Screening Market, 2018-2029
Figure 7.12: France: Carrier Screening Market, 2018-2029
Figure 7.13: Italy: Carrier Screening Market, 2018-2029
Figure 7.14: Spain: Carrier Screening Market, 2018-2029
Figure 7.15: The Netherlands: Carrier Screening Market, 2018-2029
Figure 7.16: Belgium: Carrier Screening Market, 2018-2029
Figure 7.17: Switzerland: Carrier Screening Market, 2018-2029
Figure 7.18: Denmark: Carrier Screening Market, 2018-2029
Figure 7.19: Rest-of-Europe: Carrier Screening Market, 2018-2029
Figure 7.20: Asia-Pacific: Carrier Screening Market, (2018-2029)
Figure 7.21: Asia-Pacific: Market Dynamics
Figure 7.22: Asia-Pacific: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.23: China: Carrier Screening Market, 2018-2029
Figure 7.24: Japan: Carrier Screening Market, 2018-2029
Figure 7.25: Australia: Carrier Screening Market, 2018-2029
Figure 7.26: India: Carrier Screening Market, 2018-2029
Figure 7.27: South Korea: Carrier Screening Market, 2018-2029
Figure 7.28: Singapore: Carrier Screening Market, 2018-2029
Figure 7.29: Rest-of-the-Asia-Pacific: Carrier Screening Market, 2018-2029
Figure 7.30: Latin America: Carrier Screening Market, (2018-2029)
Figure 7.31: Latin America: Market Dynamics
Figure 7.32: Latin America: Carrier Screening Market (by Country), 2018 and 2029
Figure 7.33: Brazil: Carrier Screening Market, 2018-2029
Figure 7.34: Mexico: Carrier Screening Market, 2018-2029
Figure 7.35: Rest-of-Latin America: Carrier Screening Market, 2018-2029
Figure 7.36: Rest-of-the-World: Carrier Screening Market, 2018-2029
Figure 8.1: Shares of Key Company Profiles
Figure 8.2: 23and Me, Inc.: Overall Product Portfolio
Figure 8.3: 23andMe Inc.: SWOT Analysis
Figure 8.4: BGI Product Offerings for Global Carrier Screening Market
Figure 8.5: BGI: SWOT Analysis
Figure 8.6: CENTOGENE AG: Overall Product Portfolio
Figure 8.7: CENTOGENE AG: SWOT Analysis
Figure 8.8: Eurofins Scientific: Overall Product Portfolio
Figure 8.9: Eurofins Scientific: Overall Financials, 2016-2018
Figure 8.10: Eurofins Scientific: Revenue (by Region), 2016-2018
Figure 8.11: Eurofins Scientific: SWOT Analysis
Figure 8.12: Gene by Gene: Overall Product Portfolio
Figure 8.13: Gene By Gene: SWOT Analysis
Figure 8.14: GenMark Diagnostics, Inc.: Overall Product Portfolio
Figure 8.15: GenMark Diagnostics, Inc.: Overall Financials, 2016-2018
Figure 8.16: GenMark Diagnostics, Inc.: R&D Expenditure, 2016-2018
Figure 8.17: GenMark Diagnostics, Inc.: SWOT Analysis
Figure 8.18: Illumina, Inc.: Overall Product Portfolio
Figure 8.19: Illumina, Inc.: Overall Financials, 2016-2018
Figure 8.20: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 8.21: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 8.22: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 8.23: Illumina, Inc.: SWOT Analysis
Figure 8.24: Invitae Corporation: Overall Product Portfolio
Figure 8.25: Invitae Corporation: Overall Financials, 2016-2018
Figure 8.26: Invitae Corporation: Revenue (by Region), 2016-2018
Figure 8.27: Invitae Corporation: R&D Expenditure, 2016-2018
Figure 8.28: Invitae Corporation: SWOT Analysis
Figure 8.29: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 8.30: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 8.31: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 8.32: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 8.33: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 8.34: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 8.35: Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 8.36: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 8.37: Myriad Genetics, Inc.: SWOT Analysis
Figure 8.38: Natera, Inc.: Overall Product Portfolio
Figure 8.39: Natera, Inc.: Overall Financials, 2016-2018
Figure 8.40: Natera, Inc.: Revenue (by Business Segment), 2016-2018
Figure 8.41: Natera, Inc.: R&D Expense, 2016-2018
Figure 8.42: Natera, Inc.: SWOT Analysis
Figure 8.43: Pathway Genomics Corporation: Overall Product Portfolio
Figure 8.44: Pathway Genomics Corporation: SWOT Analysis
Figure 8.45: Product Portfolio: Quest Diagnostics Incorporated
Figure 8.46: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 8.47: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 8.48: Quest Diagnostics Incorporated: SWOT Analysis
Figure 8.49: Sema4: Overall Product Portfolio
Figure 8.50: Sema4: SWOT Analysis
Figure 8.51: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 8.52: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 8.53: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 8.54: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 8.55: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 8.56: Thermo Fisher Scientific Inc.: SWOT Analysis
